Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10358895 | 0.90 | SCN4A (0.49) | KDM4EMAPTL3MBTL1SMN1; SMN2TDP1 | |
| SCHEMBL9349699 | 0.86 | MAPT (0.45) | KDM4EMAPTL3MBTL1SMN1; SMN2TDP1 | |
| SCHEMBL10359370 | 0.85 | KDM4E (0.59) | KDM4EMAPTL3MBTL1SMN1; SMN2TDP1 | |
| SCHEMBL17565185 | 0.82 | KDM4E (0.40) | KDM4EMAPTL3MBTL1SMN1; SMN2TDP1 | |
| SCHEMBL660641 | 0.79 | MAPT (0.51) | KDM4EMAPTL3MBTL1SMN1; SMN2TDP1 | |
| SCHEMBL9503906 | 0.78 | KDM4E (0.64) | KDM4EMAPTL3MBTL1SMN1; SMN2TDP1 | |
| SCHEMBL10506536 | 0.77 | MAPT (0.49) | KDM4EMAPTL3MBTL1SMN1; SMN2TDP1 | |
| SCHEMBL11336983 | 0.75 | SCN4A (0.54) | KDM4EMAPTL3MBTL1SMN1; SMN2TDP1 | |
| SCHEMBL1890174 | 0.75 | KDM4E (0.57) | KDM4EMAPTL3MBTL1SMN1; SMN2TDP1 | |
| SCHEMBL17565216 | 0.75 | KDM4E (0.36) | KDM4EMAPTL3MBTL1SMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090035313-A1 | Compounds | PFIZER INC. | 2009-02-05 | — | — | US | disclosed |
| EP-1651641-B1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LTD (GB) | 2007-05-23 | — | — | EP | disclosed |
| WO-2005009995-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
| EP-0391942-A1 | PROCESS FOR THE PREPARATION OF ARYLOXYACETIC ACID | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1990-10-17 | — | — | EP | disclosed |
| US-4935540-A | OXIDIZING ARYLOXYETHANOL IN PRESENCE OF PALLADIUM AND THALLIU M ON CARBON CATALYST, ACIDIFYING | EASTMAN CHEMICAL COMPANY | 1990-06-19 | — | — | US | disclosed |
| WO-1989003378-A1 | PROCESS FOR THE PREPARATION OF ARYLOXYACETIC ACID | EASTMAN KODAK COMPANY (US) | 1989-04-20 | — | — | WO | disclosed |
| US-4804777-A | OXIDATION OF ARYLOXYETHANOL USING PALLADIUM, SILVER, CARBON CATALYST | EASTMAN KODAK COMPANY (US) | 1989-02-14 | — | — | US | disclosed |
| EP-0011793-B1 | PROCESS FOR PREPARING ARYLOXYACETIC ACIDS | BAYER AG (DE) | 1981-09-02 | — | — | EP | disclosed |
| US-4255152-A | USING A DISPERSE DYE, WATER, AND AN ADDUCT OF ETHYLENE, PROPYLENE, OR STYRENE OXIDE AND A CYCLIC-SUBSTITUTED PHENOL; LEVELLING | CIBA-GEIGY CORPORATION (US) | 1981-03-10 | — | — | US | disclosed |
| US-4238625-A | ACTIVATORS OF LEAD AND/OR BISMUTH AND/OR THEIR COMPOUNDS FOR OXIDATION WITH PLATINUM OR PALLADIUM CATALYST | BAYER AKTIENGESELLSCHAFT (DE) | 1980-12-09 | — | — | US | disclosed |
| EP-0011793-A1 | Process for preparing aryloxyacetic acids | BAYER AG (DE) | 1980-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090035313-A1 | Compounds | NQO1, NAMPT, NNT | KDM4E 3109/4885MAPT 3157/4885L3MBTL1 4529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.